These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 23806074)

  • 1. Efavirenz stimulates HIV-1 reverse transcriptase RNase H activity by a mechanism involving increased substrate binding and secondary cleavage activity.
    Muchiri JM; Li D; Dykes C; Bambara RA
    Biochemistry; 2013 Jul; 52(29):4981-90. PubMed ID: 23806074
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transient kinetic analyses of the ribonuclease H cleavage activity of HIV-1 reverse transcriptase in complex with efavirenz and/or a β-thujaplicinol analogue.
    Herman BD; Sluis-Cremer N
    Biochem J; 2013 Oct; 455(2):179-84. PubMed ID: 23927736
    [TBL] [Abstract][Full Text] [Related]  

  • 3. N348I in HIV-1 reverse transcriptase can counteract the nevirapine-mediated bias toward RNase H cleavage during plus-strand initiation.
    Biondi MJ; Beilhartz GL; McCormick S; Götte M
    J Biol Chem; 2010 Aug; 285(35):26966-26975. PubMed ID: 20530477
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efavirenz accelerates HIV-1 reverse transcriptase ribonuclease H cleavage, leading to diminished zidovudine excision.
    Radzio J; Sluis-Cremer N
    Mol Pharmacol; 2008 Feb; 73(2):601-6. PubMed ID: 18024510
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Similarities and differences in the RNase H activities of human immunodeficiency virus type 1 reverse transcriptase and Moloney murine leukemia virus reverse transcriptase.
    Gao HQ; Sarafianos SG; Arnold E; Hughes SH
    J Mol Biol; 1999 Dec; 294(5):1097-113. PubMed ID: 10600369
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evidence that HIV-1 reverse transcriptase employs the DNA 3' end-directed primary/secondary RNase H cleavage mechanism during synthesis and strand transfer.
    Purohit V; Balakrishnan M; Kim B; Bambara RA
    J Biol Chem; 2005 Dec; 280(49):40534-43. PubMed ID: 16221683
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reduced fitness in cell culture of HIV-1 with nonnucleoside reverse transcriptase inhibitor-resistant mutations correlates with relative levels of reverse transcriptase content and RNase H activity in virions.
    Wang J; Bambara RA; Demeter LM; Dykes C
    J Virol; 2010 Sep; 84(18):9377-89. PubMed ID: 20592075
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dissecting the effects of DNA polymerase and ribonuclease H inhibitor combinations on HIV-1 reverse-transcriptase activities.
    Shaw-Reid CA; Feuston B; Munshi V; Getty K; Krueger J; Hazuda DJ; Parniak MA; Miller MD; Lewis D
    Biochemistry; 2005 Feb; 44(5):1595-606. PubMed ID: 15683243
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanisms that prevent template inactivation by HIV-1 reverse transcriptase RNase H cleavages.
    Purohit V; Roques BP; Kim B; Bambara RA
    J Biol Chem; 2007 Apr; 282(17):12598-609. PubMed ID: 17337733
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The HIV-1 reverse transcriptase mutants G190S and G190A, which confer resistance to non-nucleoside reverse transcriptase inhibitors, demonstrate reductions in RNase H activity and DNA synthesis from tRNA(Lys, 3) that correlate with reductions in replication efficiency.
    Wang J; Dykes C; Domaoal RA; Koval CE; Bambara RA; Demeter LM
    Virology; 2006 May; 348(2):462-74. PubMed ID: 16504235
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Unique progressive cleavage mechanism of HIV reverse transcriptase RNase H.
    Wisniewski M; Balakrishnan M; Palaniappan C; Fay PJ; Bambara RA
    Proc Natl Acad Sci U S A; 2000 Oct; 97(22):11978-83. PubMed ID: 11035788
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mutants of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase resistant to nonnucleoside reverse transcriptase inhibitors demonstrate altered rates of RNase H cleavage that correlate with HIV-1 replication fitness in cell culture.
    Archer RH; Dykes C; Gerondelis P; Lloyd A; Fay P; Reichman RC; Bambara RA; Demeter LM
    J Virol; 2000 Sep; 74(18):8390-401. PubMed ID: 10954539
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of HIV-1 reverse transcriptase connection subdomain mutations on polypurine tract removal and initiation of (+)-strand DNA synthesis.
    Betancor G; Álvarez M; Marcelli B; Andrés C; Martínez MA; Menéndez-Arias L
    Nucleic Acids Res; 2015 Feb; 43(4):2259-70. PubMed ID: 25662223
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alizarine derivatives as new dual inhibitors of the HIV-1 reverse transcriptase-associated DNA polymerase and RNase H activities effective also on the RNase H activity of non-nucleoside resistant reverse transcriptases.
    Esposito F; Kharlamova T; Distinto S; Zinzula L; Cheng YC; Dutschman G; Floris G; Markt P; Corona A; Tramontano E
    FEBS J; 2011 May; 278(9):1444-57. PubMed ID: 21348941
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Template-primer binding affinity and RNase H cleavage specificity contribute to the strand transfer efficiency of HIV-1 reverse transcriptase.
    Luczkowiak J; Matamoros T; Menéndez-Arias L
    J Biol Chem; 2018 Aug; 293(35):13351-13363. PubMed ID: 29991591
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ribonuclease H/DNA Polymerase HIV-1 Reverse Transcriptase Dual Inhibitor: Mechanistic Studies on the Allosteric Mode of Action of Isatin-Based Compound RMNC6.
    Corona A; Meleddu R; Esposito F; Distinto S; Bianco G; Masaoka T; Maccioni E; Menéndez-Arias L; Alcaro S; Le Grice SF; Tramontano E
    PLoS One; 2016; 11(1):e0147225. PubMed ID: 26800261
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selective interaction of the human immunodeficiency virus type 1 reverse transcriptase nonnucleoside inhibitor efavirenz and its thio-substituted analog with different enzyme-substrate complexes.
    Maga G; Ubiali D; Salvetti R; Pregnolato M; Spadari S
    Antimicrob Agents Chemother; 2000 May; 44(5):1186-94. PubMed ID: 10770750
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of second-strand transfer requirements and RNase H cleavages catalyzed by human immunodeficiency virus type 1 reverse transcriptase (RT) and E478Q RT.
    Snyder CS; Roth MJ
    J Virol; 2000 Oct; 74(20):9668-79. PubMed ID: 11000239
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Defects in primer-template binding, processive DNA synthesis, and RNase H activity associated with chimeric reverse transcriptases having the murine leukemia virus polymerase domain joined to Escherichia coli RNase H.
    Guo J; Wu W; Yuan ZY; Post K; Crouch RJ; Levin JG
    Biochemistry; 1995 Apr; 34(15):5018-29. PubMed ID: 7536033
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efavirenz binding to HIV-1 reverse transcriptase monomers and dimers.
    Braz VA; Holladay LA; Barkley MD
    Biochemistry; 2010 Jan; 49(3):601-10. PubMed ID: 20039714
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.